Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The safety and efficacy of Methylene Blue MMX modified release tablets administered to subjects undergoing screening or surveillance colonoscopy.

Next Previous
Trial Profile

The safety and efficacy of Methylene Blue MMX modified release tablets administered to subjects undergoing screening or surveillance colonoscopy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylthioninium chloride-Cosmo (Primary)
  • Indications Adenoma; Colorectal cancer
  • Focus Diagnostic use; Registrational
  • Sponsors Cosmo Pharmaceuticals; Cosmo Technologies

    • Most Recent Events

    • 21 Aug 2020 According to a Cosmo Pharmaceuticals media release, based on this study the European Commission (EC) has approved Methylthioninium Chloride Cosmo, prolonged release tablets (Methylene Blue MMX) for the visualization of colorectal lesions during colonoscopies. The Centralized European licence will be effective simultaneously in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.
    • 12 Mar 2019 FDA Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER) denied Cosmo's last appeal while reiterating the need of a phase III confirmatory trial for approval of the drug.Company has no intention to peruse any additional appeal with the FDA. The company intends to conduct a phase III confirmatory trial and will present a new clinical protocol to the FDA with different endpoints.
    • 05 Jun 2018 Results presented at the Digestive Disease Week 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top